BACKGROUND: Since the initial reports on use of MammoSite accelerated partial breast irradiation (APBI) for treatment of ductal carcinoma in situ (DCIS), additional follow-up data were collected. We hypothesized that APBI delivered via MammoSite would continue to be well tolerated, associated with a good cosmetic outcome, and carry a low risk for recurrence in patients with DCIS. MATERIALS AND METHODS: From 2002-2004, 194 patients with DCIS were enrolled in a registry trial to assess the MammoSite. Follow-up data were available for all 194 patients. Median follow-up was 54.4 months; 63 patients had at least 5 years of follow-up. Data obtained included patient-, tumor-, and treatment-related factors, and recurrence incidence. RESULTS: Of the 194 patients, 87 (45%) had the MammoSite placed at lumpectomy; 107 patients (55%) had the device placed postlumpectomy. In the first year of follow-up, 16 patients developed a breast infection, though the method of device placement was not associated with infection risk. Also, 46 patients developed a seroma that was associated with applicator placement at the time of lumpectomy (P = 0.001). For patients with at least 5 years of follow-up, 92% had favorable cosmetic results. There were 6 patients (3.1%) who had an ipsilateral breast recurrence, with 1 (0.5%) experiencing recurrence in the breast and axilla, for a 5-year actuarial local recurrence rate of 3.39%. CONCLUSIONS: During an extended follow-up period, APBI delivered via MammoSite continued to be well tolerated for patients with DCIS. Use of this device may make lumpectomy possible for patients who would otherwise choose mastectomy because of barriers associated with standard radiation therapy.
BACKGROUND: Since the initial reports on use of MammoSite accelerated partial breast irradiation (APBI) for treatment of ductal carcinoma in situ (DCIS), additional follow-up data were collected. We hypothesized that APBI delivered via MammoSite would continue to be well tolerated, associated with a good cosmetic outcome, and carry a low risk for recurrence in patients with DCIS. MATERIALS AND METHODS: From 2002-2004, 194 patients with DCIS were enrolled in a registry trial to assess the MammoSite. Follow-up data were available for all 194 patients. Median follow-up was 54.4 months; 63 patients had at least 5 years of follow-up. Data obtained included patient-, tumor-, and treatment-related factors, and recurrence incidence. RESULTS: Of the 194 patients, 87 (45%) had the MammoSite placed at lumpectomy; 107 patients (55%) had the device placed postlumpectomy. In the first year of follow-up, 16 patients developed a breast infection, though the method of device placement was not associated with infection risk. Also, 46 patients developed a seroma that was associated with applicator placement at the time of lumpectomy (P = 0.001). For patients with at least 5 years of follow-up, 92% had favorable cosmetic results. There were 6 patients (3.1%) who had an ipsilateral breast recurrence, with 1 (0.5%) experiencing recurrence in the breast and axilla, for a 5-year actuarial local recurrence rate of 3.39%. CONCLUSIONS: During an extended follow-up period, APBI delivered via MammoSite continued to be well tolerated for patients with DCIS. Use of this device may make lumpectomy possible for patients who would otherwise choose mastectomy because of barriers associated with standard radiation therapy.
Authors: Anthony E Dragun; Jennifer L Harper; Joseph M Jenrette; Debajyoti Sinha; David J Cole Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-26 Impact factor: 7.038
Authors: Pamela R Benitez; Martin E Keisch; Frank Vicini; Alan Stolier; Troy Scroggins; Alonzo Walker; Julia White; Peter Hedberg; Mary Hebert; Doug Arthur; Vic Zannis; Coral Quiet; Oscar Streeter; Mel Silverstein Journal: Am J Surg Date: 2007-10 Impact factor: 2.565
Authors: John M Watkins; Jennifer L Harper; Anthony E Dragun; Michael S Ashenafi; Debajyoti Sinha; Jun Li; David J Cole; Joseph M Jenrette Journal: Brachytherapy Date: 2008-09-07 Impact factor: 2.362
Authors: Martin Keisch; Frank Vicini; Peter Beitsch; Coral Quiet; Angela Keleher; Delia Garcia; Howard Snider; Mark Gittleman; Victor Zannis; Henry Kuerer Journal: Am J Surg Date: 2009-10 Impact factor: 2.565
Authors: Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-15 Impact factor: 7.038
Authors: Frank Vicini; Peter D Beitsch; Coral A Quiet; Angela J Keleher; Delia Garcia; Howard C Snider; Mark A Gittleman; Victor J Zannis; Henry M Kuerer; Maureen Lyden Journal: Cancer Date: 2008-02-15 Impact factor: 6.860
Authors: A Berrington de Gonzalez; R E Curtis; E Gilbert; C D Berg; S A Smith; M Stovall; E Ron Journal: Br J Cancer Date: 2009-11-24 Impact factor: 7.640
Authors: R Souchon; M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2014-01 Impact factor: 3.621
Authors: Daniel J Ferraro; Adam A Garsa; Todd A DeWees; Julie A Margenthaler; Michael Naughton; Rebecca Aft; William E Gillanders; Timothy Eberlein; Melissa A Matesa; Imran Zoberi Journal: Radiat Oncol Date: 2012-03-29 Impact factor: 3.481
Authors: Arif Y Shaikh; Michael A LaCombe; Hongyan Du; Vathsala T Raghavan; Ranjeev K Nanda; William D Bloomer Journal: Radiat Oncol Date: 2012-02-06 Impact factor: 3.481
Authors: Richard J Lee; Laura A Vallow; Sarah A McLaughlin; Katherine S Tzou; Stephanie L Hines; Jennifer L Peterson Journal: Int J Surg Oncol Date: 2012-07-18
Authors: Daniel M Trifiletti; Kara D Romano; Shayna L Showalter; Kelli A Reardon; Bruce Libby; Timothy N Showalter Journal: Breast Cancer (Dove Med Press) Date: 2015-07-29